Please ensure Javascript is enabled for purposes of website accessibility

First biopharmaceutical company locates to MediaCity

MediaCity and F2G are pleased to announce, F2G Ltd., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening fungal infections with a high unmet medical need, has moved its UK headquarters to MediaCity in Salford, Greater Manchester.

The new F2G office space within the flexible ARRIVE workspace in MediaCity’s Blue tower allows the company room for future expansion, and access to the White and Tomorrow facilities including additional space for hosting events for its entire UK workforce and partners.

Stephen Kirk, Head of Property for MediaCity, said, “F2G’s work in the treatment of life threatening fungal infections is groundbreaking and as a world class tech, digital and innovation hub which attracts many dynamic sectors from fintech and gaming to medical science we’re delighted F2G has based its UK headquarters here.”

Mike Birch, Chief Operating Officer of F2G, added, “MediaCity was an easy choice to make for our new UK headquarters because of its proximity to our research facility in Eccles and the sense of community that has been created amongst the companies that call this place home. We look forward to being an active member of the MediaCity community.”

Manchester is a big part of F2G’s history – its major scientific discoveries around the new class of antifungals called, orotomides, were made in a research lab less than a mile away from MediaCity. The company was established in Manchester leveraging the teams’ fungal genetics expertise to discover cellular targets to use in drug discovery. For twenty years the team has been on a journey to unlock the potential of its science and is now on the verge of bringing an entirely new class of systemic antifungal agents to treat patients with life-threatening systemic fungal infections.